Highest-materiality recent filing
Outset Medical Q1 revenue down 6% to $27.9M; gross margin expands to 43.4%
Revenue $27.9M (-6% YoY); recurring revenue $22.5M roughly flat.
Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M
Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).
FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.
Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange
Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.
Outset Medical Q3 revenue $29.4M (+3%); cuts FY 2025 revenue guidance to $115-120M
Net loss $17.8M vs $27.9M a year ago; non-GAAP net loss $12M vs $20.2M.
Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M
Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).
Outset Medical appoints Renee Gaeta as CFO; reaffirms $115M-$125M revenue guidance
Renee Gaeta appointed CFO effective June 3, 2025; succeeds Nabeel Ahmed who is leaving.
On May 30, 2025, the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”) appointed Renee Gaeta as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 3, 2025.
Max materiality 0.75 · Median 0.75 · Most common event earnings